{"id":"tildrakizumab","rwe":[{"pmid":"41906525","year":"2026","title":"Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.","finding":"","journal":"International journal of dermatology","studyType":"Clinical Study"},{"pmid":"41903016","year":"2026","title":"Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.","finding":"","journal":"Dermatology and therapy","studyType":"Clinical Study"},{"pmid":"41838287","year":"2026","title":"Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.","finding":"","journal":"Dermatology and therapy","studyType":"Clinical Study"},{"pmid":"41836845","year":"2026","title":"Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.","finding":"","journal":"Proceedings (Baylor University. Medical Center)","studyType":"Clinical Study"},{"pmid":"30000026","year":"2006","title":"Tildrakizumab.","finding":"","journal":"","studyType":"Clinical Study"}],"_fda":{"id":"7718538c-3c74-4470-9951-cf9634ab2f31","set_id":"c6a322bb-51b9-4f0e-8642-62a9682ffcde","openfda":{"nui":["N0000192799","N0000192798"],"unii":["DEW6X41BEK"],"route":["SUBCUTANEOUS"],"rxcui":["2053453","2053458"],"spl_id":["7718538c-3c74-4470-9951-cf9634ab2f31"],"brand_name":["ILUMYA"],"spl_set_id":["c6a322bb-51b9-4f0e-8642-62a9682ffcde"],"package_ndc":["47335-177-10","47335-177-01","47335-177-95","47335-177-96"],"product_ndc":["47335-177"],"generic_name":["TILDRAKIZUMAB-ASMN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TILDRAKIZUMAB"],"pharm_class_epc":["Interleukin-23 Antagonist [EPC]"],"pharm_class_moa":["Interleukin-23 Antagonists [MoA]"],"manufacturer_name":["Sun Pharmaceutical Industries, Inc."],"application_number":["BLA761067"],"is_original_packager":[true]},"version":"18","pregnancy":["8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors outcomes in women with plaque psoriasis who become pregnant while being treated with or who are exposed to ILUMYA during pregnancy. These patients should be encouraged to enroll in this registry by calling MotherToBaby a service of the Organization of Teratology Information Specialists (OTIS) at 1-866-626-6847 or by visiting the website https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn. Risk Summary Limited available data with ILUMYA use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. Monoclonal antibodies are actively transported across the placenta (see Clinical Considerations). An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, an increase in neonatal death was observed at 59 times the MRHD [see Data below]. The clinical significance of this nonclinical finding is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Therefore, ILUMYA may be present in infants exposed in utero . The potential clinical impact of tildrakizumab exposure in infants exposed in utero should be considered. Data Animal Data In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118 (22 days from parturition). No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg (159 times the MRHD of 100 mg, based on AUC comparison). Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose (6 times the MRHD based on AUC comparison), and four monkeys at 100 mg/kg dose (59 times the MRHD based on AUC comparison). The clinical significance of these nonclinical findings is unknown. No tildrakizumab-related adverse effects were noted in the remaining infants from birth through 6 months of age."],"overdosage":["10 OVERDOSAGE In the event of overdosage, monitor the patient for any signs or symptoms of adverse reactions, administer appropriate symptomatic treatment immediately, and contact Poison Control at 1-800-222-1222."],"description":["11 DESCRIPTION Tildrakizumab-asmn is a humanized IgG1/k antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23). Tildrakizumab-asmn is produced in a recombinant Chinese hamster ovary (CHO) cell line and has an approximate molecular mass of 147 kilodaltons. ILUMYA (tildrakizumab-asmn) injection, for subcutaneous use, is a sterile, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle. The syringe is fitted with a passive needle guard and a needle cover. Each 1 mL single-dose prefilled syringe contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied ILUMYA (tildrakizumab-asmn) Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA is supplied as one single-dose prefilled syringe per carton that delivers 1 mL of a 100 mg/mL solution. NDC 47335-177-95 Each prefilled syringe is equipped with a passive needle guard and a needle cover. Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use. Do not freeze. Do not shake. ILUMYA can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton to protect from light. Once stored at room temperature, do not place back in the refrigerator. If not used within 30 days, discard ILUMYA. Do not store ILUMYA above 25°C (77°F)."],"spl_medguide":["Medication Guide ILUMYA ® (e-LOOM-me-a) (tildrakizumab-asmn) injection, for subcutaneous use What is the most important information I should know about ILUMYA? ILUMYA may cause serious side effects, including: Serious allergic reactions. Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: feel faint swelling of your face, eyelids, lips, mouth, tongue or throat skin rash trouble breathing or throat tightness chest tightness Infections. ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your phlegm (mucus) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal See “What are the possible side effects of ILUMYA?” for more information about side effects. What is ILUMYA? ILUMYA is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). It is not known if ILUMYA is safe and effective in children under 18 years of age. Do not use ILUMYA if you have had a severe allergic reaction to tildrakizumab or any of the other ingredients in ILUMYA. See the end of this Medication Guide for a complete list of ingredients in ILUMYA. Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you: have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?” have an infection that does not go away or that keeps coming back have TB or have been in close contact with someone with TB recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA. are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby. If you become pregnant during treatment with ILUMYA, you are encouraged to enroll in the pregnancy registry. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider or call 1-866-626-6847 to enroll in this registry or visit https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn. are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive ILUMYA? ILUMYA should only be given to you by a healthcare provider. ILUMYA is given as an injection under your skin (subcutaneous injection) in areas of your body such as your thighs, stomach area (abdomen), or upper arm. If you miss a follow-up appointment and do not receive your dose of ILUMYA, schedule another appointment as soon as possible. What are the possible side effects of ILUMYA? ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?” The most common side effects of ILUMYA include: upper respiratory infections injection site reactions diarrhea These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of ILUMYA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about ILUMYA that is written for health professionals. What are the ingredients in ILUMYA? Active ingredient: tildrakizumab-asmn Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection, USP. Manufactured by: Sun Pharmaceutical Industries Limited Mumbai, Maharashtra India 400 063 U.S. License No. 2092 U.S. Patent No. 8,404,813; 8,293,883 and 9,809,648 Tildrakizumab-asmn (active ingred.) Product of South Korea. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 ILUMYA is a registered trademark of Sun Pharmaceutical Industries Limited © 2025 Sun Pharmaceutical Industries Limited All rights reserved This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 12/2025"],"geriatric_use":["8.5 Geriatric Use A total of 1083 subjects were exposed to ILUMYA 100 mg during Phase 2 and 3 trials. A total of 92 subjects were 65 years or older, and 17 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they responded differently from younger subjects [see Clinical Pharmacology (12.3) ] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of ILUMYA in pediatric patients (<18 years of age) have not been established."],"effective_time":"20251225","clinical_studies":["14 CLINICAL STUDIES Plaque Psoriasis In two multicenter, randomized, double-blind, placebo-controlled trials (Trial 2 [NCT01722331] and Trial 3 [NCT01729754]), 926 subjects were treated with ILUMYA 100 mg (N=616) or placebo (N=310). Subjects had a Physician Global Assessment (PGA) score of ≥3 (moderate) on a 5-point scale of overall disease severity, Psoriasis Area and Severity Index (PASI) score ≥12, and a minimum body surface area (BSA) involvement of 10%. Subjects with guttate, erythrodermic, or pustular psoriasis were excluded. In both trials, subjects were randomized to either placebo or ILUMYA (100 mg at Week 0, Week 4, and every twelve weeks thereafter [Q12W]) up to 64 weeks. Trials 2 and 3 assessed the changes from baseline to Week 12 in the two co-primary endpoints: PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score. PGA of 0 (“cleared”) or 1 (“minimal”), the proportion of subjects with a PGA of 0 or 1 and at least a 2-point improvement. Other evaluated outcomes in Trials 2 and 3 included the proportion of subjects who achieved a reduction from baseline in PASI score of at least 90% (PASI 90) and a reduction of 100% in PASI score (PASI 100) at Week 12 and maintenance of efficacy up to Week 64. In both trials, subjects in the ILUMYA 100 mg and placebo treatment groups were predominantly men (69%) and White (80%), with a mean age of 46 years. At baseline, these subjects had a median affected BSA of 27%, a median PASI score of 17.8, and approximately 33% had a PGA score of 4 (“marked”) or 5 (“severe”). Approximately 34% had received prior phototherapy, 39% had received prior conventional systemic therapy, and 18% had received prior biologic therapy for the treatment of psoriasis. Approximately 16% of subjects had a history of psoriatic arthritis. Clinical Response at Week 12 The results of Trials 2 and 3 are presented in Table 2. Table 2 : Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 2 and 3 (NRI*) * NRI = Non-Responder Imputation † Co-Primary Endpoints ‡ PGA score of 0 (“cleared”) or 1 (“minimal”) Trial 2 ( NCT01722331) Trial 3 ( NCT01729754) ILUMYA 100 mg (N=309) n (%) Placebo (N=154) n (%) ILUMYA 100 mg (N=307) n (%) Placebo (N=156) n (%) PGA of 0 or 1 †,‡ 179 (58) 11 (7) 168 (55) 7 (4) PASI 75 † 197 (64) 9 (6) 188 (61) 9 (6) PASI 90 107 (35) 4 (3) 119 (39) 2 (1) PASI 100 43 (14) 2 (1) 38 (12) 0 (0) Examination of age, gender, race, and previous treatment with a biologic did not identify differences in response to ILUMYA among these subgroups at Week 12. Maintenance of Response and Durability of Response In Trial 2, subjects originally randomized to ILUMYA and who were responders at Week 28 (i.e., PASI 75) were re-randomized to an additional 36 weeks of either maintaining the same dose of ILUMYA Q12W (every twelve weeks) or placebo. At Week 28, 229 (74%) subjects treated with ILUMYA 100 mg were PASI 75 responders. At Week 64, 84% of subjects who continued on ILUMYA 100 mg Q12W maintained PASI 75 compared to 22% of subjects who were re-randomized to placebo. In addition, for subjects who were re-randomized and also had a PGA score of 0 or 1 at Week 28, 69% of subjects who continued on ILUMYA 100 mg Q12W maintained this response (PGA 0 or 1) at Week 64 compared to 14% of subjects who were re-randomized to placebo. For PASI 75 responders at Week 28 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to loss of PASI 75 was approximately 20 weeks. In addition, for subjects who were re-randomized to placebo and also had a PGA score of 0 or 1 at Week 28, the median time to loss of PGA score of 0 or 1 was approximately 16 weeks. Psoriasis of the Scalp In a multicenter, randomized, double-blind, placebo-controlled trial (Trial 4 [NCT03897088]) 231 subjects with moderate to severe psoriasis of the scalp (IGA Scalp score of 3 or 4) were treated subcutaneously with ILUMYA 100 mg (n=117) or placebo (n=114) at Weeks 0 and 4. Of the 231 randomized subjects, 217 subjects completed Part 1 (Day 1 to Week 16). In Part 2 of the trial, subjects previously randomized to placebo were switched to ILUMYA 100 mg at Weeks 16, 20, 32, and 44, and those in the ILUMYA 100 mg arm continued to receive ILUMYA 100 mg at Weeks 16, 28, 40, and 52. The trial population was 79% White, 8% Black or African American, 6% Asian, 3% Native Hawaiian or Other Pacific Islander, 2% American Indian or Alaska Native, and 2% Other; for ethnicity, 65% of subjects identified as Not Hispanic or Latino. The trial population was 60% male and the mean age was 45 years. At baseline, these subjects had a median affected scalp surface area of 50%, a median PASI score of 16.7, and IGA Scalp score of 3 (“moderate”) or 4 (“severe”) in 81% and 16%, respectively. The primary endpoint was the proportion of subjects with IGA Scalp score of “clear” and “almost clear” with at least 2-point reduction from Baseline at Week 16. Other evaluated outcomes included the proportion of subjects achieving a) Psoriasis Scalp Severity Index (PSSI) 90 (≥90% improvement from Baseline in PSSI) at Week 16; b) PSSI 90 at Week 12; and c) IGA Scalp score of “clear” or “almost clear” with at least 2-point reduction from Baseline at Week 12. The efficacy results from Trial 4 are presented in Table 3. Table 3: Efficacy Results for Primary and Secondary Endpoints in Subjects with Moderate to Severe Psoriasis of the Scalp in Trial 4 (mITT, NRI*) Note: IGA = Investigator Global Assessment. PSSI = psoriasis scalp severity index. * NRI = Non-responder imputation; mITT = modified Intent-to-treat, all randomized subjects, excluding subjects enrolled early in the trial evaluated under a different IGA Scalp scale. Trial 4 (NCT03897088) ILUMYA 100 mg (N=89) n (%) Placebo (N=82) n (%) Primary Endpoint IGA Scalp Response Rate for score 0 or 1 (clear or almost clear) at Week 16 with at least 2-point reduction from baseline score 44 (49) 6 (7) Secondary Endpoints PSSI 90 Response Rate at Week 16 54 (61) 4 (5) IGA Scalp Response Rate for score 0 or 1 (clear or almost clear) at Week 12 with at least 2-point reduction from baseline score 41 (46) 4 (5) PSSI 90 Response Rate at Week 12 43 (48) 2 (2) Psoriasis of the Nail In a randomized, multicenter, double-blind, placebo-controlled trial (Trial 5 [NCT03897075]), 99 subjects with moderate to severe psoriasis of the nail received subcutaneous ILUMYA 100 mg (N=51) or placebo (N=48) at Weeks 0, 4, and 16. Of the 99 randomized subjects, 78 subjects completed Part 1 (Day 1 to Week 28) of the trial. The trial population was 79% White, 2% Black or African American, 15% Asian and 4% Other; for ethnicity, 62% of subjects identified as Not Hispanic or Latino. The trial population was 71% male and the mean age was 46 years. At baseline, these subjects had a median Modified Nail Psoriasis Severity Index (mNAPSI) score of 34 and a median PASI score of 16. The primary endpoint was the proportion of subjects who achieved at least a 75% improvement from baseline in total mNAPSI at Week 28. The efficacy results from Trial 5 are presented in Table 4. TABLE 4: Efficacy Results for the Modified Nail Psoriasis Severity Index in Subjects with Moderate to Severe Psoriasis of the Nail in Trial 5 (ITT, NRI*) ITT = Intent to Treat. mNAPSI = modified Nail Psoriasis Severity Index * NRI = Non-responder Imputation Trial 5 ILUMYA 100mg N=51 n (%) Placebo N=48 n (%) Proportion of subjects who achieve at least a 75% improvement from baseline in total mNAPSI at Week 28 13 (26) 2 (4)"],"pharmacodynamics":["12.2 Pharmacodynamics No formal pharmacodynamics studies have been conducted with ILUMYA."],"pharmacokinetics":["12.3 Pharmacokinetics Tildrakizumab pharmacokinetics increases proportionally over a dose range from 50 mg to 200 mg (0.5 to 2 times the approved recommended dosage) following subcutaneous administration in subjects with plaque psoriasis. Steady-state concentrations were achieved by Week 16 following subcutaneous administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter. At the 100 mg dose at Week 16, the mean (± SD) steady-state trough concentrations ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state C max was 8.1 mcg/mL (34%). Absorption The absolute bioavailability of tildrakizumab was estimated to be 73-80% following subcutaneous injection. The peak concentration (C max ) was reached by approximately 6 days. Distribution The geometric mean (CV%) volume of distribution is 10.8 L (24%). Elimination The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%). Metabolism The metabolic pathway of tildrakizumab has not been characterized. As a humanized IgG1/k monoclonal antibody, tildrakizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG. Specific Populations No clinically significant differences in the pharmacokinetics of tildrakizumab were observed based on age (≥18 years). No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of tildrakizumab. Body Weight Tildrakizumab concentrations were lower in subjects with higher body weight. Drug Interaction Studies Cytochrome P450 Substrates The AUC inf of dextromethorphan (CYP2D6 substrate) increased by 20% when used concomitantly with tildrakizumab 200 mg (two times the approved recommended dose) administered subcutaneously at Weeks 0 and 4 in subjects with plaque psoriasis. No clinically significant changes in AUC inf of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) were observed."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Infections [see Warnings and Precautions (5.2) ] Most common (≥1%) adverse reactions associated with ILUMYA treatment are upper respiratory infections, injection site reactions, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Plaque Psoriasis In clinical trials, a total of 1994 subjects with plaque psoriasis were treated with ILUMYA, of which 1083 subjects were treated with ILUMYA 100 mg. Of these, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months. Data from three placebo-controlled trials (Trials 1, 2, and 3) in 705 subjects (mean age 46 years, 71% males, 81% white) were pooled to evaluate the safety of ILUMYA (100 mg administered subcutaneously at Weeks 0 and 4, followed by every 12 weeks [Q12W]) [see Clinical Studies (14) ] . Placebo-Controlled Period (Weeks 0-16 of Trial 1 and Weeks 0-12 of Trials 2 and 3) Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the ILUMYA group than in the placebo group. Table 1: Adverse Reactions Occurring in ≥1% of Subjects in the ILUMYA Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3 * Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. †Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage. Adverse Reaction ILUMYA 100 mg (N=705) N (%) Placebo (N=355) N (%) Upper respiratory infections* 98 (14) 41 (12) Injection site reactions † 24 (3) 7 (2) Diarrhea 13 (2) 5 (1) During the placebo-controlled period of Trials 1, 2, and 3, adverse reactions that occurred at rates less than 1% but greater than 0.1% in the ILUMYA group and at a higher rate than in the placebo group included dizziness and pain in extremity. Cases of angioedema and urticaria were reported in ILUMYA-treated subjects in clinical trials . Safety through Week 52/64 Through Week 52 (Trials 1 and 3) and Week 64 (Trial 2), no new adverse reactions were identified with ILUMYA use and the frequency of the adverse reactions was similar to that observed during the placebo-controlled period. Psoriasis of the Scalp The safety of ILUMYA was assessed in a multicenter, randomized, double-blind, placebo-controlled trial (Trial 4) in 231 subjects with psoriasis of the scalp [ see Clinical Studies (14) ]. No new safety signals were identified through follow-up to Week 72. Psoriasis of the Nail The safety of ILUMYA was assessed in a multicenter, randomized, double-blind, placebo-controlled trial (Trial 5) in 99 subjects with psoriasis of the nail [ see Clinical Studies (14) ]. No new safety signals were identified through Week 28. 6.2 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies. Up to Week 64, approximately 6.5% of subjects treated with ILUMYA 100 mg developed antibodies to tildrakizumab. Of the subjects who developed antibodies to tildrakizumab, approximately 40% (2.5% of all subjects receiving ILUMYA) had antibodies that were classified as neutralizing. Development of neutralizing antibodies to tildrakizumab was associated with lower serum tildrakizumab concentrations and reduced efficacy."],"contraindications":["4 CONTRAINDICATIONS ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients [see Warnings and Precautions (5.1) ]. Serious hypersensitivity reaction to tildrakizumab or to any of the excipients. ( 4 )"],"spl_medguide_table":["
ILUMYA® (e-LOOM-me-a)(tildrakizumab-asmn)injection, for subcutaneous use
What is the most important information I should know about ILUMYA?ILUMYA may cause serious side effects, including:Serious allergic reactions. Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
feel faintswelling of your face, eyelids, lips, mouth, tongue or throatskin rashtrouble breathing or throat tightness chest tightness
Infections. ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
fever, sweats, or chillscoughshortness of breathblood in your phlegm (mucus)muscle acheswarm, red, or painful skin or sores on your body different from your psoriasisweight lossdiarrhea or stomach painburning when you urinate or urinating more often than normal
See “What are the possible side effects of ILUMYA?” for more information about side effects.
What is ILUMYA? ILUMYA is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).It is not known if ILUMYA is safe and effective in children under 18 years of age.
Do not use ILUMYA if you have had a severe allergic reaction to tildrakizumab or any of the other ingredients in ILUMYA. See the end of this Medication Guide for a complete list of ingredients in ILUMYA.
Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”have an infection that does not go away or that keeps coming backhave TB or have been in close contact with someone with TBrecently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby. If you become pregnant during treatment with ILUMYA, you are encouraged to enroll in the pregnancy registry. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider or call 1-866-626-6847 to enroll in this registry or visit https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn. are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive ILUMYA?
ILUMYA should only be given to you by a healthcare provider.ILUMYA is given as an injection under your skin (subcutaneous injection) in areas of your body such as your thighs, stomach area (abdomen), or upper arm.If you miss a follow-up appointment and do not receive your dose of ILUMYA, schedule another appointment as soon as possible.
What are the possible side effects of ILUMYA?ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”The most common side effects of ILUMYA include:
upper respiratory infectionsinjection site reactionsdiarrhea
These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of ILUMYA.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about ILUMYA that is written for health professionals.
What are the ingredients in ILUMYA?Active ingredient: tildrakizumab-asmnInactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection, USP.Manufactured by: Sun Pharmaceutical Industries LimitedMumbai, Maharashtra India 400 063 U.S. License No. 2092 U.S. Patent No. 8,404,813; 8,293,883 and 9,809,648 Tildrakizumab-asmn (active ingred.) Product of South Korea. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 ILUMYA is a registered trademark of Sun Pharmaceutical Industries Limited © 2025 Sun Pharmaceutical Industries Limited All rights reserved
"],"mechanism_of_action":["12.1 Mechanism of Action Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines. 12.2 Pharmacodynamics No formal pharmacodynamics studies have been conducted with ILUMYA. 12.3 Pharmacokinetics Tildrakizumab pharmacokinetics increases proportionally over a dose range from 50 mg to 200 mg (0.5 to 2 times the approved recommended dosage) following subcutaneous administration in subjects with plaque psoriasis. Steady-state concentrations were achieved by Week 16 following subcutaneous administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter. At the 100 mg dose at Week 16, the mean (± SD) steady-state trough concentrations ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state C max was 8.1 mcg/mL (34%). Absorption The absolute bioavailability of tildrakizumab was estimated to be 73-80% following subcutaneous injection. The peak concentration (C max ) was reached by approximately 6 days. Distribution The geometric mean (CV%) volume of distribution is 10.8 L (24%). Elimination The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%). Metabolism The metabolic pathway of tildrakizumab has not been characterized. As a humanized IgG1/k monoclonal antibody, tildrakizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG. Specific Populations No clinically significant differences in the pharmacokinetics of tildrakizumab were observed based on age (≥18 years). No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of tildrakizumab. Body Weight Tildrakizumab concentrations were lower in subjects with higher body weight. Drug Interaction Studies Cytochrome P450 Substrates The AUC inf of dextromethorphan (CYP2D6 substrate) increased by 20% when used concomitantly with tildrakizumab 200 mg (two times the approved recommended dose) administered subcutaneously at Weeks 0 and 4 in subjects with plaque psoriasis. No clinically significant changes in AUC inf of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) were observed."],"indications_and_usage":["1 INDICATIONS AND USAGE ILUMYA ® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity: If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. ( 5.1 ) Infections : ILUMYA may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, consider discontinuing ILUMYA until the infection resolves. ( 5.2 ) Pretreatment Evaluation for Tuberculosis (TB): Evaluate for TB prior to initiating treatment. ( 5.3 ) Immunizations : Avoid use of live vaccines. ( 5.4 ) 5.1 Hypersensitivity Cases of angioedema and urticaria occurred in ILUMYA treated subjects in clinical trials. If a serious hypersensitivity reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy [see Adverse Reactions (6.1) ]. 5.2 Infections ILUMYA may increase the risk of infection. Although infections were more common in the ILUMYA group (23%), the difference in frequency of infections between the ILUMYA group and the placebo group (22%) was less than 1% during the placebo-controlled period. However, subjects with active infections or a history of recurrent infections were not included in clinical trials. Upper respiratory infections occurred more frequently in the ILUMYA group than in the placebo group [see Adverse Reactions (6.1) ] . The rates of serious infections for the ILUMYA group and the placebo group were ≤0.3%. Treatment with ILUMYA should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ILUMYA. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, monitor the patient closely and consider discontinuation of ILUMYA until the infection resolves [see Adverse Reactions (6.1) ] . 5.3 Pretreatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Initiate treatment of latent TB prior to administering ILUMYA. In clinical trials, of 55 subjects with latent TB who were concurrently treated with ILUMYA and appropriate TB prophylaxis, no subjects developed active TB (during the mean follow-up of 56.5 weeks). One other subject developed TB while receiving ILUMYA. Monitor patients for signs and symptoms of active TB during and after ILUMYA treatment. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Do not administer ILUMYA to patients with active TB infection. 5.4 Immunizations Prior to initiating therapy with ILUMYA, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with ILUMYA. No data are available on the response to live or inactive vaccines."],"clinical_studies_table":["
Table 2: Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 2 and 3 (NRI*)
* NRI = Non-Responder Imputation† Co-Primary Endpoints‡ PGA score of 0 (“cleared”) or 1 (“minimal”)
Trial 2 (NCT01722331)Trial 3 (NCT01729754)
ILUMYA 100 mg (N=309) n (%)Placebo (N=154) n (%)ILUMYA 100 mg (N=307) n (%) Placebo (N=156) n (%)
PGA of 0 or 1†,‡179 (58)11 (7)168 (55)7 (4)
PASI 75†197 (64)9 (6)188 (61)9 (6)
PASI 90107 (35)4 (3)119 (39)2 (1)
PASI 10043 (14)2 (1)38 (12)0 (0)
","
Table 3: Efficacy Results for Primary and Secondary Endpoints in Subjects with Moderate to Severe Psoriasis of the Scalp in Trial 4 (mITT, NRI*)
Note: IGA = Investigator Global Assessment. PSSI = psoriasis scalp severity index. * NRI = Non-responder imputation; mITT = modified Intent-to-treat, all randomized subjects, excluding subjects enrolled early in the trial evaluated under a different IGA Scalp scale.
Trial 4 (NCT03897088)
ILUMYA 100 mg(N=89)n (%)Placebo(N=82)n (%)
Primary Endpoint
IGA Scalp Response Rate for score 0 or 1 (clear or almost clear) at Week 16 with at least 2-point reduction from baseline score 44 (49) 6 (7)
Secondary Endpoints
PSSI 90 Response Rate at Week 1654 (61)4 (5)
IGA Scalp Response Rate for score 0 or 1 (clear or almost clear) at Week 12 with at least 2-point reduction from baseline score41 (46)4 (5)
PSSI 90 Response Rate at Week 1243 (48)2 (2)
","
TABLE 4: Efficacy Results for the Modified Nail Psoriasis Severity Index in Subjects with Moderate to Severe Psoriasis of the Nail in Trial 5 (ITT, NRI*)
ITT = Intent to Treat.mNAPSI = modified Nail Psoriasis Severity Index* NRI = Non-responder Imputation
Trial 5
ILUMYA 100mgN=51n (%)PlaceboN=48n (%)
Proportion of subjects who achieve at least a 75% improvement from baseline in total mNAPSI at Week 2813 (26)2 (4)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of ILUMYA. No effects on fertility parameters were observed in male or female cynomolgus monkeys that were administered tildrakizumab at subcutaneous or intravenous doses up to 140 mg/kg once every two weeks for 3 months (133 or 155 times the MRHD, respectively, based on AUC comparison). The monkeys were not mated to evaluate fertility."],"adverse_reactions_table":["
Table 1: Adverse Reactions Occurring in ≥1% of Subjects in the ILUMYA Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3
* Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. †Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage.
Adverse ReactionILUMYA100 mg(N=705)N (%)Placebo(N=355)N (%)
Upper respiratory infections*98 (14)41 (12)
Injection site reactions†24 (3)7 (2)
Diarrhea13 (2)5 (1)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide). Instruct patients and/or caregivers to read the Medication Guide before starting ILUMYA therapy and to reread the Medication Guide each time the prescription is renewed. Advise patients of the potential benefits and risks of ILUMYA. Hypersensitivity Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions (5.1) ]. Infections Instruct patients of the importance of communicating any history of infections to the doctor and contacting their doctor if they develop any symptoms of infection [see Warnings and Precautions (5.2) ]. Immunizations Instruct patients to inform the healthcare practitioner that they are taking ILUMYA prior to a potential vaccination since the use of live vaccine is not recommended [see Warnings and Precautions (5.4) ]. Pregnancy Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to ILUMYA during pregnancy [ see Use in Specific Populations, Pregnancy (8.1) ]. Manufactured by: Sun Pharmaceutical Industries Limited Mumbai, Maharashtra India 400 063 U.S. License No. 2092 U.S. Patent No. 8,404,813; 8,293,883 and 9,809,648 Tildrakizumab-asmn (active ingred.) Product of South Korea. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 ILUMYA is a registered trademark of Sun Pharmaceutical Industries Limited ©2025 Sun Pharmaceutical Industries Limited All rights reserved Rev. DEC 2025 10009296-08"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION See the full prescribing information for recommended evaluations and immunizations prior to treatment. ( 2.1 ) Administer by subcutaneous injection. ( 2.2 ) Recommended dosage is 100 mg at Weeks 0, 4, and every 12 weeks thereafter. ( 2.2 ) 2.1 Recommended Evaluation and Immunization Prior to Treatment Initiation Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA [see Warnings and Precautions ( 5.3 )] . Consider completion of all age appropriate immunizations according to current immunization guidelines. [see Warnings and Precautions ( 5.4 )] 2.2 Dosage ILUMYA is administered by subcutaneous injection. The recommended dosage is 100 mg at Weeks 0, 4, and every 12 weeks thereafter. Each syringe contains 1 mL of 100 mg/mL tildrakizumab-asmn. 2.3 Important Administration Instructions ILUMYA should only be administered by a healthcare provider. Administer ILUMYA subcutaneously. Each prefilled syringe is for single-dose only. Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe. If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regularly scheduled interval. 2.4 Preparation and Administration of ILUMYA Before injection, remove ILUMYA carton from the refrigerator, and let the prefilled syringe (in the ILUMYA carton with the lid closed) sit at room temperature for 30 minutes. Follow the instructions on the ILUMYA carton to remove the prefilled syringe correctly, and remove only when ready to inject. Do not pull off the needle cover until you are ready to inject. Inspect ILUMYA visually for particulate matter and discoloration prior to administration. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Do not use if the liquid contains visible particles or the syringe is damaged. Air bubbles may be present; there is no need to remove them. Choose an injection site with clear skin and easy access (such as abdomen, thighs, or upper arm). Do not administer 2 inches around the navel or where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, do not inject into scars, stretch marks, or blood vessels. While holding the body of the syringe, pull the needle cover straight off (do not twist) and discard. Inject ILUMYA subcutaneously as recommended [see Dosage and Administration (2.3) ] . Press down the blue plunger until it can go no further. This activates the safety mechanism that will ensure full retraction of the needle after the injection is given. Remove the needle from the skin entirely before letting go of the blue plunger. After the blue plunger is released, the safety lock will draw the needle inside the needle guard. Discard any unused portion. Dispose of used syringe. image-1 image-2 image-3"],"spl_product_data_elements":["ILUMYA tildrakizumab-asmn TILDRAKIZUMAB TILDRAKIZUMAB HISTIDINE HISTIDINE MONOHYDROCHLORIDE POLYSORBATE 80 SUCROSE WATER clear to slightly opalescent, colorless to slightly yellow solution"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/mL solution in a single-dose prefilled syringe. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Injection: 100 mg/mL solution in a single-dose prefilled syringe. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors outcomes in women with plaque psoriasis who become pregnant while being treated with or who are exposed to ILUMYA during pregnancy. These patients should be encouraged to enroll in this registry by calling MotherToBaby a service of the Organization of Teratology Information Specialists (OTIS) at 1-866-626-6847 or by visiting the website https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn. Risk Summary Limited available data with ILUMYA use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. Monoclonal antibodies are actively transported across the placenta (see Clinical Considerations). An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, an increase in neonatal death was observed at 59 times the MRHD [see Data below]. The clinical significance of this nonclinical finding is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Therefore, ILUMYA may be present in infants exposed in utero . The potential clinical impact of tildrakizumab exposure in infants exposed in utero should be considered. Data Animal Data In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118 (22 days from parturition). No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg (159 times the MRHD of 100 mg, based on AUC comparison). Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose (6 times the MRHD based on AUC comparison), and four monkeys at 100 mg/kg dose (59 times the MRHD based on AUC comparison). The clinical significance of these nonclinical findings is unknown. No tildrakizumab-related adverse effects were noted in the remaining infants from birth through 6 months of age. 8.2 Lactation Risk Summary There are no data on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. Tildrakizumab was detected in the milk of monkeys [ see Data ] . The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition. Data Animal Data Tildrakizumab was detected in breast milk of monkeys in the pre- and postnatal developmental study described in 8.1. The mean tildrakizumab concentrations in milk were approximately 0.09 – 0.2% of that in serum on postpartum days 28 and 91. 8.4 Pediatric Use Safety and effectiveness of ILUMYA in pediatric patients (<18 years of age) have not been established. 8.5 Geriatric Use A total of 1083 subjects were exposed to ILUMYA 100 mg during Phase 2 and 3 trials. A total of 92 subjects were 65 years or older, and 17 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they responded differently from younger subjects [see Clinical Pharmacology (12.3) ] ."],"package_label_principal_display_panel":["Package/Label Display Panel NDC 47335-177-95 Rx only ILUMYA ® tildrakizumab-asmn injection 100 mg/mL For Subcutaneous Use Only Dispense the enclosed Medication Guide to each patient. Single-dose prefilled syringe. Discard unused portion. Sterile Solution - Contains No Preservative Sun Pharmaceutical Industries, Inc. image-4"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of ILUMYA. No effects on fertility parameters were observed in male or female cynomolgus monkeys that were administered tildrakizumab at subcutaneous or intravenous doses up to 140 mg/kg once every two weeks for 3 months (133 or 155 times the MRHD, respectively, based on AUC comparison). The monkeys were not mated to evaluate fertility."]},"tags":[{"label":"Interleukin-23 Antagonist","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"Interleukin-23","category":"target"},{"label":"IL12B","category":"gene"},{"label":"IL23A","category":"gene"},{"label":"L04AC17","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Plaque psoriasis","category":"indication"},{"label":"Sun Pharma Global","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"366 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"227 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"103 reports"},{"date":"","signal":"PSORIASIS","source":"FDA FAERS","actionTaken":"90 reports"},{"date":"","signal":"PRODUCT STORAGE ERROR","source":"FDA FAERS","actionTaken":"74 reports"},{"date":"","signal":"SELF-MEDICATION","source":"FDA FAERS","actionTaken":"74 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"69 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"65 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"55 reports"}],"commonSideEffects":[{"effect":"Upper respiratory infections","drugRate":"14%","severity":"common","_validated":true},{"effect":"Injection site reactions","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Pain in extremity","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Limited available data with ILUMYA use in pregnant women are insufficient to inform drug associated risk of adverse developmental outcomes. Human IgG is known to cross the placental barrier; therefore, ILUMYA may be transferred from the mother to the fetus. An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, small increase in neonatal death was observed at 59 times the MRHD see Data ].The clinical significance of this nonclinical finding is unknown.All pregnancies have background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.DataAnimal DataIn an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118 (22 days from parturition). No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg (159 times the MRHD).","Geriatric use":"A total of 1083 subjects were exposed to ILUMYA 100 mg during Phase and trials. total of 92 subjects were 65 years or older, and 17 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects [see Clinical Pharmacology (12.3) ].","Paediatric use":"Safety and effectiveness of ILUMYA in pediatric patients (<18 years of age) have not been established."}},"trials":[],"aliases":[],"company":"Sun Pharma Global","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TILDRAKIZUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:41:50.196319+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:42:22.023646+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:41:56.904947+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:41:50.214996+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:41:45.626227+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TILDRAKIZUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:41:58.674171+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:44.646258+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:44.646310+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:42:11.316957+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:44.646319+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:42:00.238491+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-23 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:59.242425+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108681/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:59.139097+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761067","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:44.646324+00:00"}},"allNames":"sunpg 1622","offLabel":[],"synonyms":["tildrakizumab","ilumya","tildrakizumab-asmn","MK-3222","SCH-900222","SUNPG 1622","SUNPG 1623"],"timeline":[{"date":"2018-03-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sun Pharma Global)"},{"date":"2018-09-17","type":"positive","source":"DrugCentral","milestone":"EMA approval (Almirall Sa)"},{"date":"2020-06-29","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Sun Pharma Japan Ltd.)"}],"aiSummary":"Sunpg 1622 is an interleukin-23 inhibitor, classified as an antibody drug. It is also known by the synonyms ILUMETRI, Ilumya, MK-3222, SCH-900222, TILDRAKIZUMAB, and TILDRAKIZUMAB.","approvals":[{"date":"2018-03-20","orphan":false,"company":"SUN PHARMA GLOBAL","regulator":"FDA"},{"date":"2018-09-17","orphan":false,"company":"ALMIRALL SA","regulator":"EMA"},{"date":"2020-06-29","orphan":false,"company":"Sun Pharma Japan Ltd.","regulator":"PMDA"}],"brandName":"Sunpg 1622","ecosystem":[{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"}],"globalPrevalence":125000000}],"mechanism":{"target":"Interleukin-23","novelty":"Follow-on","targets":[{"gene":"IL12B","source":"DrugCentral","target":"Interleukin-23","protein":"Interleukin-12 subunit beta"},{"gene":"IL23A","source":"DrugCentral","target":"Interleukin-23","protein":"Interleukin-23 subunit alpha"}],"moaClass":"Interleukin-23 Antagonists","modality":"Monoclonal Antibody","drugClass":"Interleukin-23 Antagonist [EPC]","explanation":"Tildrakizumab is humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.","oneSentence":"Tildrakizumab blocks the action of Interleukin-23, a protein that promotes inflammation.","technicalDetail":"Tildrakizumab acts as a competitive antagonist to IL-23 by binding to its p19 subunit, thereby inhibiting its interaction with the IL-23 receptor and subsequent downstream signaling pathways involved in inflammation.","_target_confidence":0.5},"commercial":{"launchDate":"2018","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2018-03-20, SUN PHARMA GLOBAL)","annualRevenue":500,"revenueSource":"Verified: Sun Pharma AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5281","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TILDRAKIZUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TILDRAKIZUMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:55:05.263558","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:42:22.024189+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"daclizumab","drugSlug":"daclizumab","fdaApproval":"1997-12-10","relationship":"same-class"},{"drugName":"basiliximab","drugSlug":"basiliximab","fdaApproval":"1998-05-12","relationship":"same-class"},{"drugName":"anakinra","drugSlug":"anakinra","fdaApproval":"2001-11-14","relationship":"same-class"},{"drugName":"rilonacept","drugSlug":"rilonacept","fdaApproval":"2008-02-27","relationship":"same-class"},{"drugName":"ustekinumab","drugSlug":"ustekinumab","fdaApproval":"2009-09-25","relationship":"same-class"},{"drugName":"tocilizumab","drugSlug":"tocilizumab","fdaApproval":"2010-01-08","relationship":"same-class"},{"drugName":"canakinumab","drugSlug":"canakinumab","fdaApproval":"2009-06-17","relationship":"same-class"},{"drugName":"secukinumab","drugSlug":"secukinumab","fdaApproval":"2015-01-21","relationship":"same-class"},{"drugName":"siltuximab","drugSlug":"siltuximab","fdaApproval":"2014-04-23","relationship":"same-class"},{"drugName":"brodalumab","drugSlug":"brodalumab","fdaApproval":"2017-02-15","relationship":"same-class"},{"drugName":"ixekizumab","drugSlug":"ixekizumab","fdaApproval":"2016-03-22","relationship":"same-class"},{"drugName":"sarilumab","drugSlug":"sarilumab","fdaApproval":"2017-05-22","relationship":"same-class"},{"drugName":"guselkumab","drugSlug":"guselkumab","fdaApproval":"2017-07-13","relationship":"same-class"},{"drugName":"risankizumab","drugSlug":"risankizumab","fdaApproval":"2019-04-23","relationship":"same-class"},{"drugName":"satralizumab","drugSlug":"satralizumab","fdaApproval":"2020-08-14","relationship":"same-class"},{"drugName":"spesolimab","drugSlug":"spesolimab","fdaApproval":"2022-09-01","relationship":"same-class"}],"genericName":"tildrakizumab","indications":{"approved":[{"id":"tildrakizumab-moderate-to-severe-plaque-psor","name":"Moderate-to-severe plaque psoriasis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy","diagnosticRequired":null,"brandNameForIndication":"Sunpg 1622"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daclizumab","brandName":"daclizumab","genericName":"daclizumab","approvalYear":"1997","relationship":"same-class"},{"drugId":"basiliximab","brandName":"basiliximab","genericName":"basiliximab","approvalYear":"1998","relationship":"same-class"},{"drugId":"anakinra","brandName":"anakinra","genericName":"anakinra","approvalYear":"2001","relationship":"same-class"},{"drugId":"rilonacept","brandName":"rilonacept","genericName":"rilonacept","approvalYear":"2008","relationship":"same-class"},{"drugId":"ustekinumab","brandName":"ustekinumab","genericName":"ustekinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"tocilizumab","brandName":"tocilizumab","genericName":"tocilizumab","approvalYear":"2010","relationship":"same-class"},{"drugId":"canakinumab","brandName":"canakinumab","genericName":"canakinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"secukinumab","brandName":"secukinumab","genericName":"secukinumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"siltuximab","brandName":"siltuximab","genericName":"siltuximab","approvalYear":"2014","relationship":"same-class"},{"drugId":"brodalumab","brandName":"brodalumab","genericName":"brodalumab","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06611163","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2025-03-21","conditions":["Moderate to Severe Genital Psoriasis"],"enrollment":206,"completionDate":"2027-02"},{"nctId":"NCT03997786","phase":"PHASE2,PHASE3","title":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-01-15","conditions":["Moderate-to-severe Chronic Plaque Psoriasis"],"enrollment":135,"completionDate":"2031-08-05"},{"nctId":"NCT04340076","phase":"PHASE4","title":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-08-20","conditions":["Psoriasis","Psoriasis Vulgaris"],"enrollment":244,"completionDate":"2025-01-31"},{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":["Active Psoriatic Arthritis"],"enrollment":296,"completionDate":"2026-04"},{"nctId":"NCT04991116","phase":"PHASE3","title":"Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2022-06-30","conditions":["Psoriatic Arthritis"],"enrollment":529,"completionDate":"2029-04"},{"nctId":"NCT04203693","phase":"","title":"Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-10-30","conditions":["Plaque Psoriasis"],"enrollment":331,"completionDate":"2024-05-02"},{"nctId":"NCT07370766","phase":"","title":"Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada","status":"RECRUITING","sponsor":"Chronicle Academy","startDate":"2025-11-25","conditions":["Psoriasis (PsO)","Moderate to Severe Psoriasis"],"enrollment":80,"completionDate":"2027-05-30"},{"nctId":"NCT03992729","phase":"","title":"Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab","status":"RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-08-29","conditions":["Pregnancy Related"],"enrollment":200,"completionDate":"2028-07-31"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT04314544","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":["Active Psoriatic Arthritis"],"enrollment":508,"completionDate":"2025-12-22"},{"nctId":"NCT04271540","phase":"PHASE4","title":"MIcrovascular dysfuNction In Moderate-severe Psoriasis","status":"COMPLETED","sponsor":"Marcelo F. Di Carli, MD, FACC","startDate":"2020-04-04","conditions":["Psoriasis","Cardiovascular Disease"],"enrollment":36,"completionDate":"2024-07-17"},{"nctId":"NCT07244744","phase":"","title":"Tilrdakizumab Almirall","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2023-06-27","conditions":["Psoriasis"],"enrollment":3,"completionDate":"2026-04-30"},{"nctId":"NCT04112810","phase":"PHASE2","title":"Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2020-03-01","conditions":["Hematologic Malignancies"],"enrollment":51,"completionDate":"2024-06-17"},{"nctId":"NCT05938361","phase":"","title":"Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clin4all","startDate":"2023-06-01","conditions":["Psoriasis Palmaris","Psoriasis Genital","Psoriasis of Scalp","Psoriasis Plantaris","Psoriasis Nail"],"enrollment":120,"completionDate":"2025-10-15"},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":["Chronic Spontaneous Urticaria (CSU)","Hidradenitis Suppurativa (HS)","Psoriasis (PsO)","Atopic Dermatitis (AD)","CTCL/ Mycosis Fungoides"],"enrollment":840,"completionDate":"2029-12-31"},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":["Psoriasis","Psoriatic Arthritis (PsA)","Cardiovascular Risk Factors","Metabolic Syndrome (MetS)","Drug Survival","Pharmacogenetics"],"enrollment":1000,"completionDate":"2024-06-01"},{"nctId":"NCT06488170","phase":"","title":"A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2024-04-04","conditions":["Plaque Psoriasis"],"enrollment":42,"completionDate":"2026-01"},{"nctId":"NCT03897075","phase":"PHASE3","title":"Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2021-05-13","conditions":["Chronic Plaque Psoriasis","Moderate to Severe Nail Psoriasis"],"enrollment":99,"completionDate":"2025-01-30"},{"nctId":"NCT06399432","phase":"NA","title":"Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-10-18","conditions":["Psoriasis"],"enrollment":36,"completionDate":"2026-07-01"},{"nctId":"NCT04823247","phase":"","title":"Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2021-11-22","conditions":["Plaque Psoriasis"],"enrollment":782,"completionDate":"2025-01-09"},{"nctId":"NCT06030076","phase":"","title":"A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2023-09-06","conditions":["Plaque Psoriasis"],"enrollment":50,"completionDate":"2025-10"},{"nctId":"NCT06029257","phase":"","title":"A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2023-11-14","conditions":["Genital Psoriasis"],"enrollment":110,"completionDate":"2026-03"},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":["Psoriasis","Psoriatic-arthritis"],"enrollment":3500,"completionDate":"2032-12"},{"nctId":"NCT03552276","phase":"PHASE2,PHASE3","title":"Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-07-11","conditions":["Psoriatic Arthritis"],"enrollment":281,"completionDate":"2023-09-18"},{"nctId":"NCT04971200","phase":"EARLY_PHASE1","title":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo","status":"COMPLETED","sponsor":"Premier Specialists, Australia","startDate":"2021-09-16","conditions":["Skin and Connective Tissue Diseases","Skin Diseases","Pigmentation Disorder","Hypopigmentation","Biologic","Vitiligo"],"enrollment":12,"completionDate":"2024-11-10"},{"nctId":"NCT05110313","phase":"PHASE4","title":"Effects of Tildrakizumab on Epigenetic Age","status":"COMPLETED","sponsor":"Carlos Wambier","startDate":"2022-04-08","conditions":["Psoriasis","Aging","Epigenetic Disorder","Inflammation; Skin"],"enrollment":30,"completionDate":"2024-05-27"},{"nctId":"NCT04541329","phase":"PHASE4","title":"Predicting Inflammatory Skin Disease Response to IL-23 Blockade","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-09-16","conditions":["Psoriasis Vulgaris"],"enrollment":7,"completionDate":"2023-01-15"},{"nctId":"NCT04458311","phase":"PHASE1,PHASE2","title":"Abiraterone Acetate in Combination With Tildrakizumab","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-01","conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":13,"completionDate":"2023-11-15"},{"nctId":"NCT05683015","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2022-08-22","conditions":["Psoriasis Vulgaris"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT05390515","phase":"PHASE4","title":"Psoriatic Immune Response to Tildrakizumab","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2022-09-01","conditions":["Psoriasis Vulgaris"],"enrollment":10,"completionDate":"2025-09-01"},{"nctId":"NCT03897088","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-03-29","conditions":["Scalp Psoriasis"],"enrollment":231,"completionDate":"2022-02-17"},{"nctId":"NCT05108766","phase":"PHASE3","title":"A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis","status":"COMPLETED","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2020-12-17","conditions":["Plaque Psoriasis"],"enrollment":220,"completionDate":"2022-07-08"},{"nctId":"NCT04229836","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-12-17","conditions":["Plaque Psoriasis"],"enrollment":178,"completionDate":"2021-11-15"},{"nctId":"NCT03718299","phase":"PHASE4","title":"A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-07-16","conditions":["Psoriasis"],"enrollment":55,"completionDate":"2021-11-05"},{"nctId":"NCT02980692","phase":"PHASE2","title":"Efficacy and Safety Study of SUNPG1623","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-04-19","conditions":["Active Psoriatic Arthritis"],"enrollment":391,"completionDate":"2019-09-24"},{"nctId":"NCT04263610","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-09-04","conditions":["Plaque Psoriasis"],"enrollment":190,"completionDate":"2022-02-16"},{"nctId":"NCT01722331","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","isPivotal":true,"startDate":"2012-12-06","conditions":["Plaque Psoriasis"],"enrollment":772,"completionDate":"2021-11-10"},{"nctId":"NCT01729754","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","isPivotal":true,"startDate":"2013-02-05","conditions":["Plaque Psoriasis"],"enrollment":1090,"completionDate":"2021-10-26"},{"nctId":"NCT01936688","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-09","conditions":["Plaque-type Psoriasis"],"enrollment":0,"completionDate":"2018-08"},{"nctId":"NCT04339595","phase":"PHASE4","title":"Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis","status":"TERMINATED","sponsor":"Almirall, S.A.","startDate":"2020-01-29","conditions":["Plaque Psoriasis"],"enrollment":47,"completionDate":"2020-07-31"},{"nctId":"NCT02980705","phase":"PHASE2","title":"Efficacy and Safety Study of SUNPG1622","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-11-06","conditions":["Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis"],"enrollment":180,"completionDate":"2019-09-03"},{"nctId":"NCT04465292","phase":"EARLY_PHASE1","title":"The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-01","conditions":["Pemphigoid, Bullous"],"enrollment":16,"completionDate":"2023-05-01"},{"nctId":"NCT04347473","phase":"PHASE4","title":"ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-06","conditions":["Psoriasis"],"enrollment":25,"completionDate":"2021-03-01"},{"nctId":"NCT01225731","phase":"PHASE2","title":"A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-25","conditions":["Psoriasis"],"enrollment":355,"completionDate":"2012-10-24"}],"_emaApprovals":[{"date":"2018-09-17","status":"Authorised","company":"ALMIRALL SA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT01722331","NCT01729754"],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"ILUMYA"}]},"crossReferences":{"MMSL":"277523","NDDF":"017483","UNII":"DEW6X41BEK","VANDF":"4037782","INN_ID":"9672","RXNORM":"2053436","UMLSCUI":"C4043954","chemblId":"CHEMBL2108681","ChEMBL_ID":"CHEMBL2108681","KEGG_DRUG":"D10400","DRUGBANK_ID":"DB14004","SNOMEDCT_US":"771591006","IUPHAR_LIGAND_ID":"8093","MESH_SUPPLEMENTAL_RECORD_UI":"C000598434"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Sun Pharmaceutical Industries, Inc.","brandName":"ILUMYA","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2018-","companyName":"Sun Pharma Global","relationship":"Original Developer"},{"period":"2018","companyName":"Almirall Sa","relationship":"EMA Licensee"},{"period":"2020","companyName":"Sun Pharma Japan Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"23 days"},"publicationCount":423,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-08 13:58:52.837985+00","atcClassification":{"source":"DrugCentral","atcCode":"L04AC17","allCodes":["L04AC17"]},"biosimilarFilings":[],"originalDeveloper":"Sun Pharma Global","recentPublications":[{"date":"2026 Mar 29","pmid":"41906525","title":"Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.","journal":"International journal of dermatology"},{"date":"2026 Mar 28","pmid":"41903016","title":"Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.","journal":"Dermatology and therapy"},{"date":"2026 Mar 16","pmid":"41838287","title":"Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.","journal":"Dermatology and therapy"},{"date":"2026","pmid":"41836845","title":"Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.","journal":"Proceedings (Baylor University. Medical Center)"},{"date":"2006","pmid":"30000026","title":"Tildrakizumab.","journal":""}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Sun Pharma Global","companyId":"sun-pharma-global","modality":"Monoclonal antibody","firstApprovalDate":"2018","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-20T00:00:00.000Z","mah":"SUN PHARMA GLOBAL","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2018-09-17T00:00:00.000Z","mah":"ALMIRALL SA","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2018-09-17T00:00:00.000Z","mah":"Almirall, S.A.","brand_name_local":"Ilumetri","application_number":"EMEA/H/C/004514"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-06-29T00:00:00.000Z","mah":"Sun Pharma Japan Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-12-19T00:00:00.000Z","mah":"SUN PHARMA GLOBAL","brand_name_local":null,"application_number":"BLA761067"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":10,"withResults":6},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:42:22.024189+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}